BusinessEsperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare ConferenceBy Nasdaq OMXFeb 15, 2017, 9:30 PM UTC
BusinessEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with HypercholesterolemiaBy Nasdaq OMXJan 25, 2017, 1:05 PM UTC
BusinessEsperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic AcidBy Nasdaq OMXJan 9, 2017, 1:05 PM UTC
BusinessEsperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic AcidBy Nasdaq OMXJan 8, 2017, 9:00 PM UTC
BusinessEsperion to Present at the 35th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 4, 2017, 10:00 PM UTC
BusinessEsperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature CommunicationsBy Nasdaq OMXNov 28, 2016, 9:30 PM UTC
BusinessEsperion Therapeutics to Present at the Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 9, 2016, 9:30 PM UTC
BusinessEsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 3, 2016, 8:06 PM UTC
